Torrent Pharma. (TORNTPHARM)

FairStock Score: 54/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Strong profit growth of 27.6% showing robust earnings expansion
• Excellent ROCE of 27.1% indicating efficient capital utilization
• Solid sales growth of 17.6% demonstrating market traction

Concerns

• High P/E ratio of 63.6 suggests expensive valuation
• Low dividend yield of 0.7% offers minimal income to investors
• DhanIQ score of 4/10 indicates mixed fundamentals despite growth

AI Analysis

Torrent Pharma is a Fast Grower company — trading at Rs 4,300 with a market cap of Rs 1.5 lakh crores. The data indicates impressive growth momentum with profits expanding at 27.6% and sales growing at 17.6%, showing strong operational execution. The company demonstrates excellent capital efficiency with a ROCE of 27.1%, meaning it generates good returns on invested capital. However, analysis suggests some valuation concerns with a P/E ratio of 63.6, indicating investors are paying a premium for future growth expectations. The modest dividend yield of 0.7% reflects the company's focus on reinvesting profits for expansion rather than rewarding shareholders immediately. Despite strong fundamentals, the DhanIQ score of 4/10 suggests mixed signals that investors may consider carefully. The pharmaceutical industry offers significant runway through domestic market expansion, international opportunities, and new product launches. Torrent's competitive positioning appears solid given its growth rates, but the high valuation multiples suggest the market has already priced in substantial future success. The expansion strategy seems to be working well based on current growth metrics, though debt levels and sustainability of this growth pace remain key factors for long-term success.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer